Rigel Pharmaceuticals, Incorporated

Bristol-myers Squibb Compnay

Rigl Pharmaceutical, Inc.

Rogel Pharmaceuticals, Inc.

Somasekhar Bhamidipati

Rajinder Paul Singh

Jeffrey Clough

Hui Li

Ankush Argade

Holger Keim

Catherine Sylvain

Donald G Payan

Esteban Masuda

Sacha Holland

Vanessa Taylor

Alexander B Rossi

Susan Molineaux

David Carroll

Sambaiah Thota

Ihab S Darwish

Jiaxin Yu

Kin Tso

Simon Shaw

Thomas Weitao Sun

Arvinder Sran

Robin Cooper

Pingyu Ding

Marina Gelman

Valentino J Stella

Todd M Kinsella

Rao Kolluri

Brian Wong

Andy Atuegbu

Vadim Markovtsov

Yan Chen

Darren J McMurtrie

John Yudhistir Ramphal

Zhushou Luo

Matthew Duncton

Carlos A Valdez

Hui Hong

Sasha J Holland

Haoran Zhao

Matt Duan

Mark Irving

Elliot B Grossbard

Lu Chou

Vadim Markovtosov

Dazhong Fan

Darren Mcmurtrie

Robert Michael Borzilleri

Upender Velaparthi

Jayakumar Sankara Warrier

Hasibur Rahaman

Kyle Defrees

Avinder Sran

Sambiah Thota

Argade Ankush

Singh Rajinder

John Ramphal

Sacha J Holland

Jeffrey Wayne Clough

Disclosed herein are embodiments of a method for treating a disease or condition in a subject, comprising administering to the subject, a pyrazole compound according to formula I. The compound may be administered as a composition, such as a spray-dried formulation. The disease or condition may be hidradenitis suppurativa, or a lymphoid neoplasm, and may be chronic myeloid leukemia or chronic myelomonocytic leukemia.

Method for treating a disease or condition using a pyrazole compound or formulation thereof

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

Heterocyclic RIP1 kinase inhibitors

RIP1K inhibitors

Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, X, Z, m, p, and Rare as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-β superfamily, and can be used to treat disease by blocking such activity.

TGF-β inhibitors

RIP1 inhibitory compounds and methods for making and using the same

The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Compositions and methods for inhibition of the JAK pathway

Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.

Tyrosine kinase inhibitors

The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The compounds may have a structure according to Formula I  The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

Heterocyclic RIP1 inhibitory compounds

Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, X, Z, m, p, and Rare as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-&#x3b2; superfamily, and can be used to treat disease by blocking such activity.

TGF-&#x3b2; inhibitors

Growing community of inventors

Foster City, CA, United States of America

Somasekhar Bhamidipati